logo-loader
viewTissue Regenix Group PLC

Tissue Regenix building its capabilities for future sustainable delivery

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott to discuss the group's interim 2018 results.

In the six months to the end of June they inked distribution agreements with Arthrex and ARMS Medical of the US and Pennine Healthcare here in the UK.

Another milestone was British regulatory sign-off for the BioRinse portfolio, while manufacturing of DermaPure, the company’s wound care product, has been successfully transferred to the CellRight facility in Texas  ahead of schedule.

Couldwell says they've identified a number of potential new commercial opportunities they are “actively pursuing”.

Quick facts: Tissue Regenix Group PLC

Price: 1.2101 GBX

AIM:TRX
Market: AIM
Market Cap: £14.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read